Clinical Trial Update: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Olvimulogene Nanivacirepvec with platinum-doublet chemotherapy and physician-chosen immune checkpoint inhibitor versus docetaxel in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Immune checkpoint inhibitor (physician's choice) (immune checkpoint inhibitor)
• Olvimulogene Nanivacirepvec (olvimulogene nanivacirepvec)

Snippet

Sponsor: Genelux Corporation | Conditions: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Status: RECRUITING